nodes	percent_of_prediction	percent_of_DWPC	metapath
Nalbuphine—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00654	0.029	CbGpPWpGaD
Nalbuphine—OPRM1—nerve—acquired immunodeficiency syndrome	0.00585	0.255	CbGeAlD
Nalbuphine—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00573	0.0254	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00507	0.0225	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00484	0.0215	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00445	0.0197	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00376	0.0167	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00365	0.0162	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00343	0.0152	CbGpPWpGaD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0034	0.0151	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0032	0.0142	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00307	0.0136	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00301	0.0133	CbGpPWpGaD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00298	0.0132	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00278	0.0123	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00271	0.012	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0027	0.012	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00259	0.0115	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00254	0.0113	CbGpPWpGaD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00252	0.0112	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00244	0.0108	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00235	0.0104	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00228	0.0101	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00227	0.0101	CbGpPWpGaD
Nalbuphine—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.00222	0.00985	CbGpPWpGaD
Nalbuphine—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.00222	0.00985	CbGpPWpGaD
Nalbuphine—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.00216	0.00958	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00206	0.00915	CbGpPWpGaD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00206	0.00914	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00206	0.00913	CbGpPWpGaD
Nalbuphine—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00193	0.0841	CbGeAlD
Nalbuphine—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00192	0.00852	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.0019	0.00842	CbGpPWpGaD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00186	0.00827	CbGpPWpGaD
Nalbuphine—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00186	0.081	CbGeAlD
Nalbuphine—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00185	0.0807	CbGeAlD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00181	0.00802	CbGpPWpGaD
Nalbuphine—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.00178	0.0777	CbGeAlD
Nalbuphine—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00174	0.00773	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00172	0.00761	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00167	0.00738	CbGpPWpGaD
Nalbuphine—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.00164	0.00218	CcSEcCtD
Nalbuphine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00164	0.00218	CcSEcCtD
Nalbuphine—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.00164	0.00218	CcSEcCtD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00164	0.00725	CbGpPWpGaD
Nalbuphine—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.00163	0.00723	CbGpPWpGaD
Nalbuphine—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.00163	0.00216	CcSEcCtD
Nalbuphine—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00163	0.00216	CcSEcCtD
Nalbuphine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00163	0.00216	CcSEcCtD
Nalbuphine—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00162	0.00216	CcSEcCtD
Nalbuphine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00162	0.00216	CcSEcCtD
Nalbuphine—Shock—Indinavir—acquired immunodeficiency syndrome	0.00162	0.00216	CcSEcCtD
Nalbuphine—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00162	0.00216	CcSEcCtD
Nalbuphine—OPRM1—blood—acquired immunodeficiency syndrome	0.00162	0.0707	CbGeAlD
Nalbuphine—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.00162	0.00216	CcSEcCtD
Nalbuphine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00162	0.00215	CcSEcCtD
Nalbuphine—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.00162	0.00215	CcSEcCtD
Nalbuphine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00162	0.00215	CcSEcCtD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00161	0.00716	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00161	0.00716	CbGpPWpGaD
Nalbuphine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00161	0.00215	CcSEcCtD
Nalbuphine—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00161	0.00215	CcSEcCtD
Nalbuphine—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.00161	0.00214	CcSEcCtD
Nalbuphine—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.0016	0.00213	CcSEcCtD
Nalbuphine—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.0016	0.00212	CcSEcCtD
Nalbuphine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00159	0.00212	CcSEcCtD
Nalbuphine—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.00159	0.00212	CcSEcCtD
Nalbuphine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00159	0.00212	CcSEcCtD
Nalbuphine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00159	0.00212	CcSEcCtD
Nalbuphine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00159	0.00212	CcSEcCtD
Nalbuphine—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.00159	0.00212	CcSEcCtD
Nalbuphine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.00158	0.00211	CcSEcCtD
Nalbuphine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.00158	0.0021	CcSEcCtD
Nalbuphine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00158	0.0021	CcSEcCtD
Nalbuphine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00158	0.0021	CcSEcCtD
Nalbuphine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00157	0.00209	CcSEcCtD
Nalbuphine—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00157	0.00696	CbGpPWpGaD
Nalbuphine—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.00156	0.00208	CcSEcCtD
Nalbuphine—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.00156	0.0681	CbGeAlD
Nalbuphine—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00156	0.00208	CcSEcCtD
Nalbuphine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00156	0.00207	CcSEcCtD
Nalbuphine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00155	0.00207	CcSEcCtD
Nalbuphine—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00155	0.00206	CcSEcCtD
Nalbuphine—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.00155	0.00206	CcSEcCtD
Nalbuphine—Shock—Efavirenz—acquired immunodeficiency syndrome	0.00153	0.00204	CcSEcCtD
Nalbuphine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00153	0.00204	CcSEcCtD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00153	0.00678	CbGpPWpGaD
Nalbuphine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00203	CcSEcCtD
Nalbuphine—Tension—Lamivudine—acquired immunodeficiency syndrome	0.00152	0.00203	CcSEcCtD
Nalbuphine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00152	0.00202	CcSEcCtD
Nalbuphine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00152	0.00202	CcSEcCtD
Nalbuphine—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.00152	0.00202	CcSEcCtD
Nalbuphine—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.00152	0.00202	CcSEcCtD
Nalbuphine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00152	0.00202	CcSEcCtD
Nalbuphine—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.00152	0.00202	CcSEcCtD
Nalbuphine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00151	0.00201	CcSEcCtD
Nalbuphine—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00151	0.00201	CcSEcCtD
Nalbuphine—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00151	0.00201	CcSEcCtD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00151	0.00668	CbGpPWpGaD
Nalbuphine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.0015	0.002	CcSEcCtD
Nalbuphine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.0015	0.002	CcSEcCtD
Nalbuphine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.0015	0.00199	CcSEcCtD
Nalbuphine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00149	0.00199	CcSEcCtD
Nalbuphine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.00149	0.00199	CcSEcCtD
Nalbuphine—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.00149	0.00199	CcSEcCtD
Nalbuphine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.00149	0.00198	CcSEcCtD
Nalbuphine—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.00149	0.00661	CbGpPWpGaD
Nalbuphine—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00149	0.00198	CcSEcCtD
Nalbuphine—Rash—Didanosine—acquired immunodeficiency syndrome	0.00148	0.00197	CcSEcCtD
Nalbuphine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00148	0.00197	CcSEcCtD
Nalbuphine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00148	0.00197	CcSEcCtD
Nalbuphine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00148	0.00197	CcSEcCtD
Nalbuphine—OPRD1—brain—acquired immunodeficiency syndrome	0.00147	0.0643	CbGeAlD
Nalbuphine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00147	0.00196	CcSEcCtD
Nalbuphine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00147	0.00196	CcSEcCtD
Nalbuphine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00147	0.00195	CcSEcCtD
Nalbuphine—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00147	0.00195	CcSEcCtD
Nalbuphine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00147	0.00195	CcSEcCtD
Nalbuphine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00195	CcSEcCtD
Nalbuphine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00146	0.00195	CcSEcCtD
Nalbuphine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00146	0.00195	CcSEcCtD
Nalbuphine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.00146	0.00194	CcSEcCtD
Nalbuphine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00146	0.00194	CcSEcCtD
Nalbuphine—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.00146	0.00194	CcSEcCtD
Nalbuphine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00146	0.00194	CcSEcCtD
Nalbuphine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.00145	0.00193	CcSEcCtD
Nalbuphine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00145	0.00193	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00145	0.00193	CcSEcCtD
Nalbuphine—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00145	0.00642	CbGpPWpGaD
Nalbuphine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00145	0.00193	CcSEcCtD
Nalbuphine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00144	0.00192	CcSEcCtD
Nalbuphine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00144	0.00192	CcSEcCtD
Nalbuphine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00144	0.00192	CcSEcCtD
Nalbuphine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.00143	0.00191	CcSEcCtD
Nalbuphine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.00143	0.0019	CcSEcCtD
Nalbuphine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00142	0.00189	CcSEcCtD
Nalbuphine—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00142	0.0063	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00142	0.00628	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00142	0.00628	CbGpPWpGaD
Nalbuphine—OPRK1—brain—acquired immunodeficiency syndrome	0.00141	0.0617	CbGeAlD
Nalbuphine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00141	0.00188	CcSEcCtD
Nalbuphine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.00141	0.00188	CcSEcCtD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00141	0.00624	CbGpPWpGaD
Nalbuphine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00141	0.00187	CcSEcCtD
Nalbuphine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.0014	0.00187	CcSEcCtD
Nalbuphine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.0014	0.00187	CcSEcCtD
Nalbuphine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.0014	0.00187	CcSEcCtD
Nalbuphine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.0014	0.00186	CcSEcCtD
Nalbuphine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.0014	0.00186	CcSEcCtD
Nalbuphine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.00139	0.00186	CcSEcCtD
Nalbuphine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00139	0.00185	CcSEcCtD
Nalbuphine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.00139	0.00185	CcSEcCtD
Nalbuphine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00139	0.00185	CcSEcCtD
Nalbuphine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00139	0.00185	CcSEcCtD
Nalbuphine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00139	0.00184	CcSEcCtD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00138	0.00613	CbGpPWpGaD
Nalbuphine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.00138	0.00184	CcSEcCtD
Nalbuphine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00138	0.00184	CcSEcCtD
Nalbuphine—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00138	0.0061	CbGpPWpGaD
Nalbuphine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00137	0.00183	CcSEcCtD
Nalbuphine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00136	0.00181	CcSEcCtD
Nalbuphine—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00136	0.00604	CbGpPWpGaD
Nalbuphine—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00136	0.00604	CbGpPWpGaD
Nalbuphine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00136	0.00181	CcSEcCtD
Nalbuphine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.00136	0.00181	CcSEcCtD
Nalbuphine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00135	0.0018	CcSEcCtD
Nalbuphine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00135	0.0018	CcSEcCtD
Nalbuphine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00135	0.0018	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00135	0.0018	CcSEcCtD
Nalbuphine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00179	CcSEcCtD
Nalbuphine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.00134	0.00179	CcSEcCtD
Nalbuphine—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00134	0.00596	CbGpPWpGaD
Nalbuphine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00134	0.00179	CcSEcCtD
Nalbuphine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00134	0.00178	CcSEcCtD
Nalbuphine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00134	0.00178	CcSEcCtD
Nalbuphine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00133	0.00177	CcSEcCtD
Nalbuphine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00133	0.00177	CcSEcCtD
Nalbuphine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00133	0.00177	CcSEcCtD
Nalbuphine—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00133	0.0059	CbGpPWpGaD
Nalbuphine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00177	CcSEcCtD
Nalbuphine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00133	0.00177	CcSEcCtD
Nalbuphine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00133	0.00177	CcSEcCtD
Nalbuphine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00176	CcSEcCtD
Nalbuphine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00132	0.00176	CcSEcCtD
Nalbuphine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.00132	0.00175	CcSEcCtD
Nalbuphine—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00132	0.0574	CbGeAlD
Nalbuphine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00131	0.00175	CcSEcCtD
Nalbuphine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00131	0.00174	CcSEcCtD
Nalbuphine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00131	0.00174	CcSEcCtD
Nalbuphine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.0013	0.00174	CcSEcCtD
Nalbuphine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.0013	0.00174	CcSEcCtD
Nalbuphine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.0013	0.00173	CcSEcCtD
Nalbuphine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.0013	0.00173	CcSEcCtD
Nalbuphine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00129	0.00172	CcSEcCtD
Nalbuphine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00129	0.00172	CcSEcCtD
Nalbuphine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00129	0.00172	CcSEcCtD
Nalbuphine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00129	0.00172	CcSEcCtD
Nalbuphine—Rash—Stavudine—acquired immunodeficiency syndrome	0.00129	0.00171	CcSEcCtD
Nalbuphine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00129	0.00171	CcSEcCtD
Nalbuphine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00128	0.00171	CcSEcCtD
Nalbuphine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00128	0.00171	CcSEcCtD
Nalbuphine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00128	0.00171	CcSEcCtD
Nalbuphine—Headache—Stavudine—acquired immunodeficiency syndrome	0.00128	0.0017	CcSEcCtD
Nalbuphine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00128	0.0017	CcSEcCtD
Nalbuphine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00128	0.0017	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00127	0.0017	CcSEcCtD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00127	0.00565	CbGpPWpGaD
Nalbuphine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00169	CcSEcCtD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00127	0.00564	CbGpPWpGaD
Nalbuphine—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00127	0.00563	CbGpPWpGaD
Nalbuphine—Rash—Abacavir—acquired immunodeficiency syndrome	0.00127	0.00169	CcSEcCtD
Nalbuphine—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.00127	0.0553	CbGeAlD
Nalbuphine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00127	0.00169	CcSEcCtD
Nalbuphine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.00127	0.00169	CcSEcCtD
Nalbuphine—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00126	0.00561	CbGpPWpGaD
Nalbuphine—Headache—Abacavir—acquired immunodeficiency syndrome	0.00126	0.00168	CcSEcCtD
Nalbuphine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00126	0.00167	CcSEcCtD
Nalbuphine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00126	0.00167	CcSEcCtD
Nalbuphine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.00125	0.00166	CcSEcCtD
Nalbuphine—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00125	0.00552	CbGpPWpGaD
Nalbuphine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00124	0.00165	CcSEcCtD
Nalbuphine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00124	0.00165	CcSEcCtD
Nalbuphine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00124	0.00165	CcSEcCtD
Nalbuphine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00123	0.00164	CcSEcCtD
Nalbuphine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.00123	0.00164	CcSEcCtD
Nalbuphine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.00164	CcSEcCtD
Nalbuphine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00123	0.00164	CcSEcCtD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00123	0.00545	CbGpPWpGaD
Nalbuphine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.00163	CcSEcCtD
Nalbuphine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00122	0.00163	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00122	0.00162	CcSEcCtD
Nalbuphine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00122	0.00162	CcSEcCtD
Nalbuphine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00122	0.00162	CcSEcCtD
Nalbuphine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.00121	0.00162	CcSEcCtD
Nalbuphine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00121	0.00161	CcSEcCtD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.0012	0.00531	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.0012	0.00531	CbGpPWpGaD
Nalbuphine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00119	0.00159	CcSEcCtD
Nalbuphine—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00119	0.0053	CbGpPWpGaD
Nalbuphine—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00119	0.0053	CbGpPWpGaD
Nalbuphine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00119	0.00159	CcSEcCtD
Nalbuphine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.00158	CcSEcCtD
Nalbuphine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00158	CcSEcCtD
Nalbuphine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00118	0.00157	CcSEcCtD
Nalbuphine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00118	0.00157	CcSEcCtD
Nalbuphine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00118	0.00157	CcSEcCtD
Nalbuphine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.00157	CcSEcCtD
Nalbuphine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.00157	CcSEcCtD
Nalbuphine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00118	0.00523	CbGpPWpGaD
Nalbuphine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00117	0.00156	CcSEcCtD
Nalbuphine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.00117	0.00156	CcSEcCtD
Nalbuphine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00117	0.00155	CcSEcCtD
Nalbuphine—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00117	0.00517	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00116	0.00516	CbGpPWpGaD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00115	0.00511	CbGpPWpGaD
Nalbuphine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00115	0.00153	CcSEcCtD
Nalbuphine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00114	0.00151	CcSEcCtD
Nalbuphine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00114	0.00151	CcSEcCtD
Nalbuphine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.0015	CcSEcCtD
Nalbuphine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00113	0.0015	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.00113	0.0015	CcSEcCtD
Nalbuphine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.0015	CcSEcCtD
Nalbuphine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00149	CcSEcCtD
Nalbuphine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00112	0.00149	CcSEcCtD
Nalbuphine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00149	CcSEcCtD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00112	0.00495	CbGpPWpGaD
Nalbuphine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.00111	0.00148	CcSEcCtD
Nalbuphine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00111	0.00148	CcSEcCtD
Nalbuphine—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00111	0.00492	CbGpPWpGaD
Nalbuphine—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00111	0.00491	CbGpPWpGaD
Nalbuphine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.0011	0.00147	CcSEcCtD
Nalbuphine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.0011	0.00146	CcSEcCtD
Nalbuphine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.0011	0.00146	CcSEcCtD
Nalbuphine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00109	0.00146	CcSEcCtD
Nalbuphine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00109	0.00145	CcSEcCtD
Nalbuphine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.00145	CcSEcCtD
Nalbuphine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.00145	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00109	0.00144	CcSEcCtD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00108	0.0048	CbGpPWpGaD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00108	0.0048	CbGpPWpGaD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00108	0.00478	CbGpPWpGaD
Nalbuphine—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00107	0.00476	CbGpPWpGaD
Nalbuphine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00107	0.00142	CcSEcCtD
Nalbuphine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00106	0.0014	CcSEcCtD
Nalbuphine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.0014	CcSEcCtD
Nalbuphine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00105	0.0014	CcSEcCtD
Nalbuphine—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00105	0.00467	CbGpPWpGaD
Nalbuphine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.0014	CcSEcCtD
Nalbuphine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.0014	CcSEcCtD
Nalbuphine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00105	0.0014	CcSEcCtD
Nalbuphine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00104	0.00139	CcSEcCtD
Nalbuphine—Rash—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00138	CcSEcCtD
Nalbuphine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00138	CcSEcCtD
Nalbuphine—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00104	0.0046	CbGpPWpGaD
Nalbuphine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.00104	0.00138	CcSEcCtD
Nalbuphine—Headache—Indinavir—acquired immunodeficiency syndrome	0.00103	0.00138	CcSEcCtD
Nalbuphine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00103	0.00137	CcSEcCtD
Nalbuphine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00102	0.00135	CcSEcCtD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00101	0.00448	CbGpPWpGaD
Nalbuphine—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00101	0.00448	CbGpPWpGaD
Nalbuphine—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00101	0.00448	CbGpPWpGaD
Nalbuphine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00101	0.00134	CcSEcCtD
Nalbuphine—OPRM1—brain—acquired immunodeficiency syndrome	0.00101	0.0439	CbGeAlD
Nalbuphine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.001	0.00133	CcSEcCtD
Nalbuphine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.001	0.00133	CcSEcCtD
Nalbuphine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000996	0.00442	CbGpPWpGaD
Nalbuphine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000991	0.00132	CcSEcCtD
Nalbuphine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00099	0.00132	CcSEcCtD
Nalbuphine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000986	0.00131	CcSEcCtD
Nalbuphine—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000986	0.00437	CbGpPWpGaD
Nalbuphine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000983	0.00131	CcSEcCtD
Nalbuphine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000982	0.00131	CcSEcCtD
Nalbuphine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00098	0.0013	CcSEcCtD
Nalbuphine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000978	0.0013	CcSEcCtD
Nalbuphine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000977	0.0013	CcSEcCtD
Nalbuphine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000976	0.0013	CcSEcCtD
Nalbuphine—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00097	0.0043	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00097	0.0043	CbGpPWpGaD
Nalbuphine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000953	0.00127	CcSEcCtD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00095	0.00421	CbGpPWpGaD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00095	0.00421	CbGpPWpGaD
Nalbuphine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000948	0.00126	CcSEcCtD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000944	0.00419	CbGpPWpGaD
Nalbuphine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000941	0.00125	CcSEcCtD
Nalbuphine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00094	0.00125	CcSEcCtD
Nalbuphine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000939	0.00125	CcSEcCtD
Nalbuphine—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000937	0.00415	CbGpPWpGaD
Nalbuphine—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000936	0.00415	CbGpPWpGaD
Nalbuphine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000934	0.00124	CcSEcCtD
Nalbuphine—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000934	0.00414	CbGpPWpGaD
Nalbuphine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000933	0.00124	CcSEcCtD
Nalbuphine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000926	0.00123	CcSEcCtD
Nalbuphine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000912	0.00121	CcSEcCtD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00091	0.00404	CbGpPWpGaD
Nalbuphine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000909	0.00121	CcSEcCtD
Nalbuphine—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000909	0.00403	CbGpPWpGaD
Nalbuphine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000896	0.00119	CcSEcCtD
Nalbuphine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000886	0.00118	CcSEcCtD
Nalbuphine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000878	0.00117	CcSEcCtD
Nalbuphine—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000877	0.00389	CbGpPWpGaD
Nalbuphine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000877	0.00117	CcSEcCtD
Nalbuphine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00087	0.00116	CcSEcCtD
Nalbuphine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000869	0.00116	CcSEcCtD
Nalbuphine—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000866	0.00384	CbGpPWpGaD
Nalbuphine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000864	0.00115	CcSEcCtD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000854	0.00379	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000851	0.00377	CbGpPWpGaD
Nalbuphine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000844	0.00112	CcSEcCtD
Nalbuphine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000838	0.00111	CcSEcCtD
Nalbuphine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000837	0.00111	CcSEcCtD
Nalbuphine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000836	0.00111	CcSEcCtD
Nalbuphine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000832	0.00111	CcSEcCtD
Nalbuphine—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000825	0.00366	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000825	0.00366	CbGpPWpGaD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000824	0.00365	CbGpPWpGaD
Nalbuphine—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00082	0.00364	CbGpPWpGaD
Nalbuphine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000819	0.00109	CcSEcCtD
Nalbuphine—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000819	0.00363	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000806	0.00357	CbGpPWpGaD
Nalbuphine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000805	0.00107	CcSEcCtD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000803	0.00356	CbGpPWpGaD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000803	0.00356	CbGpPWpGaD
Nalbuphine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000799	0.00106	CcSEcCtD
Nalbuphine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000798	0.00106	CcSEcCtD
Nalbuphine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000793	0.00106	CcSEcCtD
Nalbuphine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000789	0.00105	CcSEcCtD
Nalbuphine—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000786	0.00348	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000769	0.00341	CbGpPWpGaD
Nalbuphine—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000768	0.00341	CbGpPWpGaD
Nalbuphine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00076	0.00337	CbGpPWpGaD
Nalbuphine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000752	0.001	CcSEcCtD
Nalbuphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000742	0.00329	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000729	0.00323	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000723	0.00321	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000723	0.00321	CbGpPWpGaD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000723	0.0032	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000719	0.00319	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000707	0.00313	CbGpPWpGaD
Nalbuphine—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000692	0.00307	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000689	0.00305	CbGpPWpGaD
Nalbuphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000651	0.00289	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00065	0.00288	CbGpPWpGaD
Nalbuphine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000642	0.00285	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000639	0.00283	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000627	0.00278	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000611	0.00271	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000611	0.00271	CbGpPWpGaD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000611	0.00271	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000597	0.00265	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000582	0.00258	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000565	0.00251	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00055	0.00244	CbGpPWpGaD
Nalbuphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00055	0.00244	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00054	0.00239	CbGpPWpGaD
Nalbuphine—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000506	0.00225	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000498	0.00221	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000496	0.0022	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000496	0.0022	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000476	0.00211	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000476	0.00211	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000466	0.00207	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000466	0.00207	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000465	0.00206	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00045	0.002	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000436	0.00194	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000435	0.00193	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00043	0.00191	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000423	0.00188	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000423	0.00188	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000419	0.00186	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000417	0.00185	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000417	0.00185	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000409	0.00181	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000409	0.00181	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000395	0.00175	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000377	0.00167	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000371	0.00165	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000371	0.00165	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000369	0.00164	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000367	0.00163	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000355	0.00157	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000353	0.00156	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000353	0.00156	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000349	0.00155	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000345	0.00153	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000345	0.00153	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000334	0.00148	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000322	0.00143	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000319	0.00142	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000319	0.00141	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000317	0.00141	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000314	0.00139	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000314	0.00139	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000311	0.00138	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000306	0.00136	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000294	0.0013	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00029	0.00129	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000282	0.00125	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00028	0.00124	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000278	0.00123	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000266	0.00118	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000263	0.00117	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000259	0.00115	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000258	0.00114	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000254	0.00113	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00025	0.00111	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00025	0.00111	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000239	0.00106	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000237	0.00105	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000235	0.00104	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000233	0.00103	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000219	0.000972	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000219	0.000972	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000218	0.000966	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000215	0.000953	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000197	0.000874	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00019	0.000843	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000187	0.000831	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000185	0.000822	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000185	0.000822	CbGpPWpGaD
Nalbuphine—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000185	0.000818	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000171	0.00076	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000168	0.000743	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000167	0.00074	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000164	0.000728	CbGpPWpGaD
Nalbuphine—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000162	0.000718	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.00015	0.000666	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000147	0.000652	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000141	0.000625	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000139	0.000616	CbGpPWpGaD
Nalbuphine—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000137	0.000607	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000127	0.000563	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000124	0.000551	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.9e-05	0.000439	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.85e-05	0.000437	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.68e-05	0.000385	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.64e-05	0.000383	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.34e-05	0.000325	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.3e-05	0.000324	CbGpPWpGaD
Nalbuphine—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.82e-05	0.000258	CbGpPWpGaD
Nalbuphine—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.1e-05	0.000226	CbGpPWpGaD
Nalbuphine—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.31e-05	0.000191	CbGpPWpGaD
